Header Logo

Jonathan Kay MD

TitleProfessor
Endowed TitleTimothy S. and Elaine L. Peterson Chair in Rheumatology
InstitutionUMass Chan Medical School
DepartmentMedicine
AddressUMass Memorial Medical Center
119 Belmont Street
Worcester MA 01605
Phone508-334-6273
vCardDownload vCard
    Other Positions
    InstitutionT.H. Chan School of Medicine
    DepartmentMedicine
    DivisionRheumatology

    InstitutionT.H. Chan School of Medicine
    DepartmentPopulation and Quantitative Health Sciences

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentImmunology and Microbiology Program

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentMasters in Clinical Investigation

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentMD/PhD Program

    InstitutionMorningside Graduate School of Biomedical Sciences
    DepartmentPopulation Health Sciences


    Collapse Biography 
    Collapse education and training
    Harvard University, Cambridge, MA, United StatesABBioChemical Sciences
    University of California, San Francisco, San Francisco, CA, United StatesMD

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Salomon-Escoto K, Stutsky M, Reed G, Hinestroza Jordan MY, Kay J, Wessolossky M. Greater HIV Viral Load Suppression in Patients Using an Integrated Health System Specialty Pharmacy. J Pharm Pract. 2025 Sep 04; 8971900251376796. PMID: 40906621.
      Citations:    
    2. Deane KD, Striebich CC, Feser ML, O'Dell JR, James JA, Sparks JA, Davis JM, Graf J, McMahon MA, Solow EB, Forbess L, Tiliakos A, Schiopu E, Danila MI, Horowitz DL, Kay J, Strickland CD, Guthridge JM, Arriens C, Grossman JM, Demoruelle MK, Bemis EA, Frazer-Abel A, Fleischer CL, Fox DA, Mikuls TR, Greenleaf M, York K, Walker S, Keyes-Elstein L, Byron M, Fedler J, Goldmuntz EA, Holers VM. A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis. Arthritis Rheumatol. 2025 Aug 29. PMID: 40884017.
      Citations:    
    3. Singh NC, Gilead T, Chakraborty A, Van Herwegen J, van Atteveldt N, Borst G, Bugden S, Jasinska K, Kay J, Pugh K, Duraiappah A. A new education agenda based on The International Science and Evidence Based Education Assessment. NPJ Sci Learn. 2025 May 10; 10(1):24. PMID: 40348805.
      Citations:    
    4. Avouac J, Kay J, Choy E. Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges. Semin Arthritis Rheum. 2025 Aug; 73:152740. PMID: 40339302.
      Citations:    
    5. Winthrop KL, Bathon J, Kerschbaumer A, Isaacs JD, Mease P, Gottenberg JE, Crow MK, Kay J, Crofford L, Baraliakos X, Bykerk V, Siebert S, Kloppenburg M, Aletaha D, McInnes IB, Huizinga T, Voll R, Gravallese EM, Breedveld FC, van Vollenhoven R, Smolen JS. Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024. Ann Rheum Dis. 2025 Jun; 84(6):927-936. PMID: 40240265.
      Citations:    
    6. Liu SH, Kay J. Disparities in Diagnosis: A Call for Equity in Radiographic Axial Spondyloarthritis Care. J Rheumatol. 2025 Apr 01; 52(4):302-304. PMID: 39955094.
      Citations:    
    7. Ogdie A, Reddy SM, Gillespie SH, Husni ME, Scher JU, Salomon-Escoto K, Kay J, Luedders BA, Curtis JR, Shields AJS, Chakravarty SD, Gong C, Walsh JA. Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. Trials. 2025 Mar 19; 26(1):96. PMID: 40102973.
      Citations:    
    8. Kay J, Nikolov NP, Weisman MH. American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17-18, 2022. Arthritis Rheumatol. 2024 Sep; 76(9):1323-1333. PMID: 38622107.
      Citations:    
    9. Shridharmurthy D, Lapane KL, Baek J, Nunes AP, Weisman MH, Kay J, Liu SH. Sex Differences in Time to Initiate Nonsteroidal Anti-Inflammatory Drugs or Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2024 08; 76(8):1149-1161. PMID: 38538532.
      Citations:    
    10. Choufani M, Kay J, Ermann J. Axial spondyloarthritis guidelines - aiming for maximum impact. Curr Opin Rheumatol. 2024 07 01; 36(4):251-260. PMID: 38661436.
      Citations:    
    11. Navarro-Comp?n V, Ramiro S, Deodhar A, Mease PJ, Rudwaleit M, de la Loge C, Fleurinck C, Taieb V, M?rup MF, Massow U, Kay J, Magrey M. Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD Open. 2024 04 10; 10(2). PMID: 38599650.
      Citations:    
    12. Winthrop KL, Mease P, Kerschbaumer A, Voll RE, Breedveld FC, Smolen JS, Gottenberg JE, Baraliakos X, Kiener HP, Aletaha D, Isaacs JD, Buch MH, Crow MK, Kay J, Crofford L, van Vollenhoven RF, Ospelt C, Siebert S, Kloppenburg M, McInnes IB, Huizinga TW, Gravallese EM. Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. Ann Rheum Dis. 2024 Mar 12; 83(4):409-416. PMID: 38123338.
      Citations: 1     Fields:    
    13. Jin R, Kruppert S, Scholz F, Bardoulat I, Karzazi K, Morand F, Kricorian G, Collier D, Kay J. Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases. Rheumatol Ther. 2024 Jun; 11(3):523-537. PMID: 38436916.
      Citations:    
    14. Kay J, Cross RK, Feldman SR, Park Y, Hanauer SB. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 02; 41(2):509-533. PMID: 38110655.
      Citations:    Fields:    Translation:Humans
    15. Reginato AM, Petri MA, Kay J. Walter Bauer, Marian Wilkins Ropes, and the Massachusetts General Hospital. Rheum Dis Clin North Am. 2024 02; 50(1):79-92. PMID: 37973290.
      Citations:    Fields:    Translation:Humans
    16. Kay J. Multiple switching studies and interchangeability of biosimilars. Lancet Rheumatol. 2023 Sep; 5(9):e499-e501. PMID: 38251493.
      Citations:    
    17. Shridharmurthy D, Lapane KL, Nunes AP, Baek J, Weisman MH, Kay J, Liu SH. Postpartum Depression in Reproductive-Age Women With and Without Rheumatic Disease: A Population-Based Matched Cohort Study. J Rheumatol. 2023 10; 50(10):1287-1295. PMID: 37399461.
      Citations:    Fields:    Translation:Humans
    18. Shridharmurthy D, Lapane KL, Baek J, Nunes A, Kay J, Liu SH. Comanagement with rheumatology and prescription biologics filled during pregnancy in women with rheumatic diseases: a retrospective analysis of US administrative claims data. BMJ Open. 2022 12 22; 12(12):e065189. PMID: 36549721.
      Citations:    Fields:    
    19. Rahrmann EP, Shorthouse D, Jassim A, Hu LP, Ortiz M, Mahler-Araujo B, Vogel P, Paez-Ribes M, Fatemi A, Hannon GJ, Iyer R, Blundon JA, Louren?o FC, Kay J, Nazarian RM, Hall BA, Zakharenko SS, Winton DJ, Zhu L, Gilbertson RJ. The NALCN channel regulates metastasis and nonmalignant cell dissemination. Nat Genet. 2022 12; 54(12):1827-1838. PMID: 36175792.
      Citations: 16     Fields:    Translation:HumansAnimals
    20. Buhigas C, Warren AY, Leung WK, Whitaker HC, Luxton HJ, Hawkins S, Kay J, Butler A, Xu Y, Woodcock DJ, Merson S, Frame FM, Sahli A, Abascal F, Martincorena I, Bova GS, Foster CS, Campbell P, Maitland NJ, Neal DE, Massie CE, Lynch AG, Eeles RA, Cooper CS, Wedge DC, Brewer DS. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates. Mol Cancer. 2022 09 22; 21(1):183. PMID: 36131292.
      Citations:    
    21. Kay J, Bock AE, Rehman M, Zhang W, Zhang M, Iikuni N, Alvarez DF. Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis. RMD Open. 2022 09; 8(2). PMID: 36180101.
      Citations:    
    22. Menter A, Cohen S, Kay J, Strand V, Gottlieb A, Hanauer S, Eduru SK, Buschke S, Lang B, Liesenfeld KH, Schaible J, McCabe D. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022 Sep; 23(5):719-728. PMID: 35934770.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    23. Shridharmurthy D, Lapane KL, Khan S, Yi E, Baek J, Kay J, Liu SH. Development and test-retest reliability of a screening tool for axial spondyloarthritis. PLoS One. 2022; 17(7):e0269494. PMID: 35802613.
      Citations: 1     Fields:    Translation:Humans
    24. Furst DE, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, Jeka S, Zielinska A, Trefler J, Bartnicka-Maslowska K, Krajewska-Wlodarczyk M, Klimiuk PA, Lee SJ, Kim SH, Bae YJ, Yang GE, Yoo JK, Kay J, Keystone E. Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Rheumatology (Oxford). 2022 04 11; 61(4):1385-1395. PMID: 34142111.
      Citations: 5     Fields:    Translation:Humans
    25. Shridharmurthy D, Khan S, Lapane KL, Yi E, Kay J, Liu SH. Development of a screening tool to identify patients with axial spondyloarthritis: a cognitive interview study. Clin Rheumatol. 2022 May; 41(5):1391-1402. PMID: 35059882.
      Citations: 1     Fields:    Translation:Humans
    26. Khan S, Shridharmurthy D, Lapane KL, Dube C, Kay J, Yi E, Liu SH. The disease burden of axial spondyloarthritis: through a gendered lens. Clin Rheumatol. 2022 Apr; 41(4):1115-1124. PMID: 34988682.
      Citations: 2     Fields:    Translation:Humans
    27. Lapane KL, Dub? C, Ferrucci K, Khan S, Kuhn KA, Yi E, Kay J, Liu SH. Patient perspectives on health care provider practices leading to an axial spondyloarthritis diagnosis: an exploratory qualitative research study. BMC Fam Pract. 2021 12 20; 22(1):251. PMID: 34930136.
      Citations: 2     Fields:    Translation:Humans
    28. Dube CE, Lapane KL, Ferrucci KA, Beccia AL, Khan SK, Yi E, Kay J, Kuhn KA, Ogdie A, Liu SH. Personal Experiences with Diagnostic Delay Among Axial Spondyloarthritis Patients: A Qualitative Study. Rheumatol Ther. 2021 Jun; 8(2):1015-1030. PMID: 34059989.
      Citations:    
    29. Lapane KL, Shridharmurthy D, Khan S, Lindstrom D, Beccia A, Yi E, Kay J, Dube C, Liu SH. Primary care physician perspectives on screening for axial spondyloarthritis: A qualitative study. PLoS One. 2021; 16(5):e0252018. PMID: 34029339.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    30. Davidson A, Brimhall D, Kay J, Keystone E, Lee SJ, Kim SH, Bae YJ, Choi EJ, Furst DE. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40?mg/0.4?mL) by autoinjector and prefilled syringe in healthy subjects. Br J Clin Pharmacol. 2021 11; 87(11):4323-4333. PMID: 33822406.
      Citations: 2     Fields:    Translation:Humans
    31. Yu KS, Jang IJ, Lim HS, Hong JH, Kim MG, Park MK, Cho DY, Park MS, Chung JY, Ghim JL, Lee S, Yoon SK, Kwon IS, Lee SJ, Kim SH, Bae YJ, Cha JB, Furst DE, Keystone E, Kay J. Pharmacokinetic equivalence of CT-P17 to high-concentration (100?mg/ml) reference adalimumab: A randomized phase I study in healthy subjects. Clin Transl Sci. 2021 07; 14(4):1280-1291. PMID: 33503313.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    32. Kay J, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, Jeka S, Zielinska A, Trefler J, Bartnicka-Maslowska K, Krajewska-Wlodarczyk M, Klimiuk PA, Lee SJ, Bae YJ, Yang GE, Yoo JK, Furst DE, Keystone E. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Res Ther. 2021 02 05; 23(1):51. PMID: 33546755.
      Citations: 8     Fields:    Translation:Humans
    33. Shridharmurthy D, Zhao D, Lapane KL, Baek J, Kay J, Liu SH. Disease Burden and Health-Related Quality of Life Among Women and Men with Spondyloarthritis: An Exploratory Analysis of a Population-Based Sample. J Womens Health (Larchmt). 2021 11; 30(11):1637-1644. PMID: 33450162.
      Citations:    Fields:    Translation:Humans
    34. Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landew? RB, Atsumi T, Burmester GR. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021 06; 80(6):727-738. PMID: 33452004.
      Citations: 33     Fields:    Translation:HumansAnimalsCTClinical Trials
    35. Alvarez DF, Wolbink G, Cronenberger C, Orazem J, Kay J. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States? BioDrugs. 2020 Dec; 34(6):723-732. PMID: 32990892.
      Citations: 9     Fields:    Translation:Humans
    36. Liu SH, Shridharmurthy D, Lapane KL, Dub? CE, Gravallese EM, Kay J. Physical Activity and Attitudes Toward Exercise in People With Axial and Peripheral Spondyloarthritis. J Rheumatol. 2021 04; 48(4):513-519. PMID: 33060306.
      Citations:    Fields:    Translation:Humans
    37. Kay J, Harigai M, Rancourt J, Dickson C, Melby T, Issa M, de la Torre I, Isaka Y, Cardoso A, Saifan C, Keystone EC, van Vollenhoven RF, Giles JT, Huizinga TW, Kremer JM. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 2020 10; 6(3). PMID: 33028675.
      Citations:    
    38. Lapane KL, Khan S, Shridharmurthy D, Beccia A, Dub? C, Yi E, Kay J, Liu SH. Primary care physician perspectives on barriers to diagnosing axial Spondyloarthritis: a qualitative study. BMC Fam Pract. 2020 09 29; 21(1):204. PMID: 32993510.
      Citations: 10     Fields:    Translation:Humans
    39. Joo W, Almario CV, Ishimori M, Park Y, Jusufagic A, Noah B, Gensler LS, Venuturupalli RS, Kay J, Weisman MH, Spiegel BMR. Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey. ACR Open Rheumatol. 2020 Jul; 2(7):391-400. PMID: 32519467.
      Citations:    
    40. Baker JF, Leonard CE, Lo Re V, Weisman MH, George MD, Kay J. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis Rheumatol. 2020 07; 72(7):1067-1071. PMID: 32253823.
      Citations: 5     Fields:    Translation:Humans
    41. Kay J. Overcoming barriers to biosimilars in inflammatory arthritis. Nat Rev Rheumatol. 2020 Feb; 16(2):65-66. PMID: 31873190.
      Citations: 1     Fields:    Translation:Humans
    42. Curtis JR, Xie F, Kay J, Kallich JD. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. Arthritis Res Ther. 2019 12 12; 21(1):285. PMID: 31831064.
      Citations: 2     Fields:    Translation:Humans
    43. Liu SH, Morais SA, Lapane KL, Kay J. Physical activity and attitudes and perceptions towards physical activity in patients with spondyloarthritis: A systematic review. Semin Arthritis Rheum. 2020 04; 50(2):289-302. PMID: 31839210.
      Citations: 3     Fields:    Translation:Humans
    44. Salomon-Escoto K, Kay J. The "Treat to Target" Approach to Rheumatoid Arthritis. Rheum Dis Clin North Am. 2019 11; 45(4):487-504. PMID: 31564292.
      Citations: 6     Fields:    Translation:Humans
    45. Kay J, Schwartzman S. Controversies in Rheumatology. Rheum Dis Clin North Am. 2019 08; 45(3):xv-xvi. PMID: 31277758.
      Citations:    Fields:    Translation:Humans
    46. Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landew? R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 07; 71(7):1101-1111. PMID: 30848558.
      Citations: 36     Fields:    Translation:Humans
    47. Kay J. Are There Benefits and Risks to Biosimilars from a Patient Perspective? Rheum Dis Clin North Am. 2019 08; 45(3):465-476. PMID: 31277756.
      Citations: 2     Fields:    Translation:Humans
    48. Kay J. A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extension. J Intern Med. 2019 06; 285(6):693-695. PMID: 30990229.
      Citations:    Fields:    Translation:Humans
    49. Jidkov L, Alexander M, Bark P, Williams JG, Kay J, Taylor P, Hemingway H, Banerjee A. Health informatics competencies in postgraduate medical education and training in the UK: a mixed methods study. BMJ Open. 2019 03 30; 9(3):e025460. PMID: 30928942.
      Citations:    
    50. Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Ann Rheum Dis. 2019 07; 78(7):872-878. PMID: 30712015.
      Citations: 10     Fields:    Translation:Humans
    51. Dzubur E, Khalil C, Almario CV, Noah B, Minhas D, Ishimori M, Arnold C, Park Y, Kay J, Weisman MH, Spiegel BMR. Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media Platforms. Arthritis Care Res (Hoboken). 2019 02; 71(2):323-330. PMID: 29781587.
      Citations: 13     Fields:    Translation:Humans
    52. Kay J, D?rner T, Emery P, Kvien TK, Breedveld FC. Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar. Ann Rheum Dis. 2020 04; 79(4):e44. PMID: 30659047.
      Citations: 6     Fields:    
    53. Olivier J, Stavrinides V, Kay J, Freeman A, Pye H, Ahmed Z, Carmona Echeverria L, Heavey S, Simmons LAM, Kanthabalan A, Arya M, Briggs T, Barratt D, Charman SC, Gelister J, Hawkes D, Hu Y, Jameson C, McCartan N, Punwani S, van der Muelen J, Moore C, Emberton M, Ahmed HU, Whitaker HC. Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI-characterized prostates. Prostate. 2018 12; 78(16):1229-1237. PMID: 30073682.
      Citations:    
    54. Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Lu YJ, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavar? S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, Corbishley C, de Bono J, Attard G, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal DE, Cooper CS, Eeles RA. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. 2018 05; 50(5):682-692. PMID: 29662167.
      Citations:    
    55. Bridges SL, White DW, Worthing AB, Gravallese EM, O'Dell JR, Nola K, Kay J, Cohen SB. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. Arthritis Rheumatol. 2018 03; 70(3):334-344. PMID: 29411547.
      Citations: 14     Fields:    Translation:Humans
    56. Gravallese EM, Kay J, Duryea J, Solomon DH. Reply. Arthritis Rheumatol. 2018 03; 70(3):476. PMID: 29193854.
      Citations:    Fields:    Translation:Humans
    57. Baecklund E, Backlin C, R?nnelid J, Toes R, Huizinga T, ?hlin E, Askling J, Hochberg FH, Klareskog L, Kay J, Smedby KE. Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. Scand J Rheumatol. 2018 07; 47(4):270-275. PMID: 29336646.
      Citations: 2     Fields:    Translation:Humans
    58. Camacho N, Van Loo P, Edwards S, Kay JD, Matthews L, Haase K, Clark J, Dennis N, Thomas S, Kremeyer B, Zamora J, Butler AP, Gundem G, Merson S, Luxton H, Hawkins S, Ghori M, Marsden L, Lambert A, Karaszi K, Pelvender G, Massie CE, Kote-Jarai Z, Raine K, Jones D, Howat WJ, Hazell S, Livni N, Fisher C, Ogden C, Kumar P, Thompson A, Nicol D, Mayer E, Dudderidge T, Yu Y, Zhang H, Shah NC, Gnanapragasam VJ, Isaacs W, Visakorpi T, Hamdy F, Berney D, Verrill C, Warren AY, Wedge DC, Lynch AG, Foster CS, Lu YJ, Bova GS, Whitaker HC, McDermott U, Neal DE, Eeles R, Cooper CS, Brewer DS. Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. PLoS Genet. 2017 Sep; 13(9):e1007001. PMID: 28945760.
      Citations:    
    59. Kay J, Schoels MM, D?rner T, Emery P, Kvien TK, Smolen JS, Breedveld FC. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018 02; 77(2):165-174. PMID: 28866648.
      Citations: 71     Fields:    Translation:Humans
    60. Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE. The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. Clin Immunol. 2018 01; 186:87-93. PMID: 28811201.
      Citations: 16     Fields:    Translation:Humans
    61. Solomon DH, Kay J, Duryea J, Lu B, Bolster MB, Yood RA, Han R, Ball S, Coleman C, Lo E, Wohlfahrt A, Sury M, Yin M, Yu Z, Zak A, Gravallese EM. Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2017 09; 69(9):1741-1750. PMID: 28544807.
      Citations: 15     Fields:    Translation:Humans
    62. Kay J, Winthrop KL. Pharmacotherapy: Biosimilar switching - "To set a form upon desired change". Nat Rev Rheumatol. 2017 07; 13(7):391-392. PMID: 28569266.
      Citations:    Fields:    
    63. Cohen S, Kay J. Biosimilars: implications for rheumatoid arthritis therapy. Curr Opin Rheumatol. 2017 05; 29(3):260-268. PMID: 28306596.
      Citations: 7     Fields:    Translation:Humans
    64. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R, Kadva A, Dimonaco S. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017 Jul; 76(7):1279-1284. PMID: 28389552.
      Citations: 37     Fields:    Translation:Humans
    65. Braun J, Kay J. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2017 Mar; 16(3):289-302. PMID: 28068848.
      Citations: 5     Fields:    Translation:Humans
    66. Goyal A, Linskey KR, Kay J, Duncan LM, Nazarian RM. Differential Expression of Hedgehog and Snail in Cutaneous Fibrosing Disorders: Implications for Targeted Inhibition. Am J Clin Pathol. 2016 Dec; 146(6):709-717. PMID: 28077400.
      Citations: 3     Fields:    Translation:Humans
    67. Stavre Z, Upchurch K, Kay J, Gravallese EM. Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis. Curr Rheumatol Rep. 2016 Dec; 18(12):72. PMID: 27812955.
      Citations: 6     Fields:    Translation:Humans
    68. Schaub S, Sirkis HM, Kay J. Imaging for Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome. Rheum Dis Clin North Am. 2016 11; 42(4):695-710. PMID: 27742022.
      Citations: 14     Fields:    Translation:Humans
    69. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou Y, Goldstein N, Braun J. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Rheumatol. 2016 12; 43(12):2120-2130. PMID: 27803138.
      Citations: 18     Fields:    Translation:Humans
    70. Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M, Perez-Ruiz F, da Rocha Castelar-Pinheiro G, Saag K, So A, Vazquez Mellado J, Weisman M, Westhoff TH, Yamanaka H, Braun J. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017 04; 76(4):632-638. PMID: 27658678.
      Citations: 47     Fields:    Translation:Humans
    71. Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis. 2017 01; 76(1):4-6. PMID: 27566795.
      Citations: 8     Fields:    
    72. Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. Clin Exp Rheumatol. 2016 Jul-Aug; 34(4 Suppl 98):69-76. PMID: 27586809.
      Citations: 12     Fields:    Translation:HumansAnimals
    73. Kay J. Editorial: Biosimilars: New or D?j? Vu? Arthritis Rheumatol. 2016 05; 68(5):1049-52. PMID: 26748580.
      Citations: 4     Fields:    
    74. Lambert J, Wyand M, Lassen C, Shneyer L, Thomson E, Knight A, Willers J, Kay J. Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. Int J Clin Pharmacol Ther. 2016 Apr; 54(4):315-22. PMID: 26952037.
      Citations: 5     Fields:    Translation:Humans
    75. D?rner T, Strand V, Cornes P, Gon?alves J, Gul?csi L, Kay J, Kvien TK, Smolen J, Tanaka Y, Burmester GR. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016 06; 75(6):974-82. PMID: 26964144.
      Citations: 69     Fields:    Translation:Humans
    76. Duryea J, Russell R, Gravallese EM, Kay J, Han R, Lu B, Solomon DH. Brief Report: Development and Validation of a Semiautomated Method to Measure Erosion Volume in Inflammatory Arthritis by Computed Tomography Scanning. Arthritis Rheumatol. 2016 Feb; 68(2):332-6. PMID: 26473501.
      Citations:    Fields:    Translation:Humans
    77. Deodhar A, Strand V, Kay J, Braun J. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016 May; 75(5):791-4. PMID: 26768406.
      Citations: 44     Fields:    Translation:Humans
    78. Todd DJ, Kay J. Gadolinium-Induced Fibrosis. Annu Rev Med. 2016; 67:273-91. PMID: 26768242.
      Citations: 18     Fields:    Translation:HumansAnimals
    79. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016 Jun; 75(6):1081-91. PMID: 26511996.
      Citations: 76     Fields:    Translation:HumansCTClinical Trials
    80. Gvozdenovic E, Wolterbeek R, Allaart CF, Brenol C, Dougados M, Emery P, Ferraccioli G, van der Heijde D, Huizinga TW, Kay J, Martin Mola E, Moots RJ, da Silva JA, Smolen J, Veale D, Landew? RB. Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database. J Clin Rheumatol. 2015 Oct; 21(7):349-54. PMID: 26398461.
      Citations: 3     Fields:    Translation:Humans
    81. Pertega-Gomes N, Vizcaino JR, Felisbino S, Warren AY, Shaw G, Kay J, Whitaker H, Lynch AG, Fryer L, Neal DE, Massie CE. Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer. Oncotarget. 2015 Aug 28; 6(25):21675-84. PMID: 26035357.
      Citations:    
    82. D?rner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015 Dec; 11(12):713-24. PMID: 26282080.
      Citations: 38     Fields:    Translation:Humans
    83. Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. Int J Rheum Dis. 2016 Nov; 19(11):1143-1156. PMID: 26259617.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    84. Casta?eda-Hern?ndez G, Gonz?lez-Ram?rez R, Kay J, Scheinberg MA. Biosimilars in rheumatology: what the clinician should know. RMD Open. 2015; 1(1):e000010. PMID: 26509046.
      Citations:    
    85. Navarro-Comp?n V, Smolen JS, Huizinga TW, Landew? R, Ferraccioli G, da Silva JA, Moots RJ, Kay J, van der Heijde D. Quality indicators in rheumatoid arthritis: results from the METEOR database. Rheumatology (Oxford). 2015 Sep; 54(9):1630-9. PMID: 25877910.
      Citations: 13     Fields:    Translation:Humans
    86. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, Dennis N, Merson S, Leongamornlert D, Zamora J, Corbishley C, Thomas S, Nik-Zainal S, O'Meara S, Matthews L, Clark J, Hurst R, Mithen R, Bristow RG, Boutros PC, Fraser M, Cooke S, Raine K, Jones D, Menzies A, Stebbings L, Hinton J, Teague J, McLaren S, Mudie L, Hardy C, Anderson E, Joseph O, Goody V, Robinson B, Maddison M, Gamble S, Greenman C, Berney D, Hazell S, Livni N, Fisher C, Ogden C, Kumar P, Thompson A, Woodhouse C, Nicol D, Mayer E, Dudderidge T, Shah NC, Gnanapragasam V, Voet T, Campbell P, Futreal A, Easton D, Warren AY, Foster CS, Stratton MR, Whitaker HC, McDermott U, Brewer DS, Neal DE. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet. 2015 Apr; 47(4):367-372. PMID: 25730763.
      Citations:    
    87. Carter BD, Abnet CC, Feskanich D, Freedman ND, Hartge P, Lewis CE, Ockene JK, Prentice RL, Speizer FE, Thun MJ, Jacobs EJ. Smoking and mortality--beyond established causes. N Engl J Med. 2015 Feb 12; 372(7):631-40. PMID: 21724294.
      Citations: 37     Fields:    Translation:Humans
    88. Smolen JS, Kay J, Doyle M, Landew? R, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Xu S, Zhou Y, Hsia EC. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor a inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther. 2015 Jan 22; 17:14. PMID: 25627338.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    89. Schmidt-Lauber C, Bossaller L, Abujudeh HH, Vladimer GI, Christ A, Fitzgerald KA, Latz E, Gravallese EM, Marshak-Rothstein A, Kay J. Gadolinium-based compounds induce NLRP3-dependent IL-1? production and peritoneal inflammation. Ann Rheum Dis. 2015 Nov; 74(11):2062-9. PMID: 24914072.
      Citations: 13     Fields:    Translation:AnimalsCells
    90. Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J. Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. Rheumatology (Oxford). 2014 Sep; 53(9):1613-7. PMID: 24706993.
      Citations: 1     Fields:    Translation:Humans
    91. Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014 Jul; 69(7):661-8. PMID: 24582176.
      Citations: 26     Fields:    Translation:Humans
    92. Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, Fiore S, Momtahen T, Yancopoulos GD, Stahl N, Inman RD. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015 Jun; 74(6):1051-7. PMID: 24550171.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    93. Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, Gravallese EM, Furst DE. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014 Feb 03; 16(1):R40. PMID: 24485007.
      Citations: 47     Fields:    Translation:Humans
    94. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015 Mar; 74(3):538-46. PMID: 24344160.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    95. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, Casado G, Detert J, El-Zorkany B, Emery P, Hajjaj-Hassouni N, Harigai M, Luo SF, Kurucz R, Maciel G, Mola EM, Montecucco CM, McInnes I, Radner H, Smolen JS, Song YW, Vonkeman HE, Winthrop K, Kay J. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014 Jan; 73(1):62-8. PMID: 24095940.
      Citations: 284     Fields:    Translation:Humans
    96. Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis. 2013 Oct; 72(10):1589-93. PMID: 23897773.
      Citations: 16     Fields:    Translation:Humans
    97. Smolen JS, Kay J, Matteson EL, Landew? R, Hsia EC, Xu S, Zhou Y, Doyle MK. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis. 2014 Oct; 73(10):1811-8. PMID: 23897769.
      Citations: 14     Fields:    Translation:Humans
    98. Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013 Oct; 52(10):1845-55. PMID: 23838027.
      Citations: 11     Fields:    Translation:Humans
    99. Kay J. Rheumatic rarities. Preface. Rheum Dis Clin North Am. 2013 May; 39(2):xv-xvi. PMID: 23597977.
      Citations:    Fields:    Translation:Humans
    100. Chopra R, Chaudhary N, Kay J. Relapsing polychondritis. Rheum Dis Clin North Am. 2013 May; 39(2):263-76. PMID: 23597963.
      Citations: 12     Fields:    Translation:Humans
    101. Le LP, Garibyan L, Lara D, Finberg KE, Iafrate AJ, Duncan LM, Kay J, Nazarian RM. Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. Am J Dermatopathol. 2013 May; 35(3):351-6. PMID: 23051628.
      Citations: 1     Fields:    Translation:Humans
    102. Kay J, Gravallese EM. Rheumatoid arthritis: erosion defined: back to basics. Nat Rev Rheumatol. 2013 Jun; 9(6):323-4. PMID: 23609778.
      Citations:    Fields:    Translation:Humans
    103. Vital EM, Kay J, Emery P. Rituximab biosimilars. Expert Opin Biol Ther. 2013 Jul; 13(7):1049-62. PMID: 23600760.
      Citations: 19     Fields:    Translation:Humans
    104. Lima XT, Alora-Palli MB, Kimball AB, Kay J. Validation of a screening instrument for nephrogenic systemic fibrosis. Arthritis Care Res (Hoboken). 2013 Apr; 65(4):637-42. PMID: 23097320.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    105. Schneeberger D, Tyndall A, Kay J, S?ndergaard KH, Carreira PE, Morgiel E, Deuschle K, Derk CT, Widuchowska M, Walker UA. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology (Oxford). 2013 Mar; 52(3):560-7. PMID: 23221323.
      Citations: 10     Fields:    Translation:Humans
    106. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012 Dec; 51 Suppl 6:vi5-9. PMID: 23221588.
      Citations: 202     Fields:    Translation:Humans
    107. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford). 2012 Dec; 51 Suppl 6:vi28-36. PMID: 23221584.
      Citations: 65     Fields:    Translation:Humans
    108. Kay J, Feagan BG, Guirguis MS, Keystone EC, Klein AV, Lubiniecki AS, Mould DR, Nyarko KA, Ridgway AA, Trudeau ME, Wang J. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. Biologicals. 2012 Nov; 40(6):517-27. PMID: 23084808.
      Citations: 4     Fields:    
    109. Bernstein EJ, Schmidt-Lauber C, Kay J. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol. 2012 Aug; 26(4):489-503. PMID: 23040363.
      Citations: 18     Fields:    Translation:Humans
    110. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology--"O brave new world". Nat Rev Rheumatol. 2012 06 05; 8(7):430-6. PMID: 22664834.
      Citations: 32     Fields:    Translation:Humans
    111. Smolen JS, Kay J, Landew? RB, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Zhou Y, Hsia EC, Doyle MK. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis. 2012 Oct; 71(10):1671-9. PMID: 22459542.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    112. Bernstein EJ, Kay J, Gibofsky A. Erratum to: Treating rheumatoid arthritis to target: an international initiative. Curr Rev Musculoskelet Med. 2011 Sep; 4(3):157. PMID: 21728012.
      Citations:    
    113. Bernstein EJ, Kay J, Gibofsky A. Treating rheumatoid arthritis to target: an international initiative. Curr Rev Musculoskelet Med. 2011 09; 4(3):79-83. PMID: 21656282.
      Citations:    
    114. Salomon-Escoto KI, Gravallese EM, Kay J. Assessment of control of rheumatoid arthritis disease activity. Best Pract Res Clin Rheumatol. 2011 Aug; 25(4):497-507. PMID: 22137920.
      Citations: 10     Fields:    Translation:Humans
    115. Lin HW, Roberts DS, Kay J, Stankovic KM. Sensorineural hearing loss following imatinib (Gleevec) administration. Otolaryngol Head Neck Surg. 2012 Feb; 146(2):335-7. PMID: 21753034.
      Citations: 8     Fields:    Translation:Humans
    116. Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology. 2011 Jul; 260(1):105-11. PMID: 21586680.
      Citations: 48     Fields:    Translation:Humans
    117. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther. 2011 May 12; 13(3):112. PMID: 21586106.
      Citations: 18     Fields:    Translation:HumansAnimals
    118. Wasko MC, Kay J, Hsia EC, Rahman MU. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken). 2011 Apr; 63(4):512-21. PMID: 21452264.
      Citations: 31     Fields:    Translation:HumansAnimals
    119. Nazarian RM, Mandal RV, Kagan A, Kay J, Duncan LM. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. J Am Acad Dermatol. 2011 Apr; 64(4):741-7. PMID: 21414498.
      Citations: 2     Fields:    Translation:Humans
    120. Kay J, Czirj?k L. Gadolinium and systemic fibrosis: guilt by association. Ann Rheum Dis. 2010 Nov; 69(11):1895-7. PMID: 20959325.
      Citations: 4     Fields:    Translation:Humans
    121. Lebiedz-Odrobina D, Kay J. Rheumatic manifestations of diabetes mellitus. Rheum Dis Clin North Am. 2010 Nov; 36(4):681-99. PMID: 21092846.
      Citations: 33     Fields:    Translation:Humans
    122. Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Khanna D, Kvien TK, Laing T, Liao K, Mease P, M?nard HA, Moreland LW, Nair R, Pincus T, Ringold S, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsk? J, Wolfe F, Hawker G. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010 Sep; 62(9):2582-91. PMID: 20872596.
      Citations: 97     Fields:    Translation:Humans
    123. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, M?nard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep; 69(9):1580-8. PMID: 20699241.
      Citations: 1279     Fields:    Translation:Humans
    124. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, M?nard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsk? J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep; 62(9):2569-81. PMID: 20872595.
      Citations: 3022     Fields:    Translation:Humans
    125. Funovits J, Aletaha D, Bykerk V, Combe B, Dougados M, Emery P, Felson D, Hawker G, Hazes JM, Huizinga T, Kay J, Kvien TK, Smolen JS, Symmons D, Tak PP, Silman A. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis. 2010 Sep; 69(9):1589-95. PMID: 20699242.
      Citations: 47     Fields:    Translation:Humans
    126. Kay J, Rahman MU. Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid. 2010 Jun 15; 4:159-70. PMID: 20694072.
      Citations:    
    127. Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am. 2010 May; 36(2):385-404. PMID: 20510240.
      Citations: 86     Fields:    Translation:HumansAnimalsCells
    128. Koreishi AF, Nazarian RM, Saenz AJ, Klepeis VE, McDonald AG, Farris AB, Colvin RB, Duncan LM, Mandal RV, Kay J. Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Arch Pathol Lab Med. 2009 Dec; 133(12):1943-8. PMID: 19961249.
      Citations: 8     Fields:    Translation:Humans
    129. Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, Schaefer PW, Kay J. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging. 2009 Dec; 30(6):1335-40. PMID: 19937927.
      Citations: 7     Fields:    Translation:Humans
    130. Kroshinsky D, Kay J, Nazarian RM. Case records of the Massachusetts General Hospital. Case 37-2009. A 46-year-old woman with chronic renal failure, leg swelling, and skin changes. N Engl J Med. 2009 Nov 26; 361(22):2166-76. PMID: 19940302.
      Citations: 3     Fields:    Translation:Humans
    131. Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology. 2009 Oct; 253(1):81-9. PMID: 19709997.
      Citations: 22     Fields:    Translation:Humans
    132. Kay J, Westhovens R. Methotrexate: the gold standard without standardisation. Ann Rheum Dis. 2009 Jul; 68(7):1081-2. PMID: 19525405.
      Citations: 5     Fields:    Translation:Humans
    133. Smolen JS, Kay J, Doyle MK, Landew? R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009 Jul 18; 374(9685):210-21. PMID: 19560810.
      Citations: 183     Fields:    Translation:HumansCTClinical Trials
    134. Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J Rheumatol. 2009 Jul; 36(7):1371-9. PMID: 19487269.
      Citations: 15     Fields:    Translation:Humans
    135. Collier DS, Grant RW, Estey G, Surrao D, Chueh HC, Kay J. Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculator. Arthritis Rheum. 2009 Apr 15; 61(4):495-500. PMID: 19333984.
      Citations: 7     Fields:    Translation:Humans
    136. Collier DS, Kay J, Estey G, Surrao D, Chueh HC, Grant RW. A rheumatology-specific informatics-based application with a disease activity calculator. Arthritis Rheum. 2009 Apr 15; 61(4):488-94. PMID: 19333976.
      Citations: 8     Fields:    Translation:Humans
    137. Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis. 2008 Dec; 67 Suppl 3:iii66-9. PMID: 19022818.
      Citations: 12     Fields:    Translation:Humans
    138. Kay J. Nephrogenic systemic fibrosis: a new concern for rheumatologists. Nat Clin Pract Rheumatol. 2008 Sep; 4(9):445. PMID: 18756271.
      Citations:    Fields:    Translation:Humans
    139. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008 Aug; 58(8):2543-8. PMID: 18668587.
      Citations: 42     Fields:    Translation:Humans
    140. Todd DJ, Kay J. Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Curr Rheumatol Rep. 2008 Jul; 10(3):195-204. PMID: 18638427.
      Citations: 8     Fields:    Translation:Humans
    141. Sarraf P, Kay J, Reginato AM. Non-crystalline and crystalline rheumatic disorders in chronic kidney disease. Curr Rheumatol Rep. 2008 Jul; 10(3):235-48. PMID: 18638433.
      Citations: 4     Fields:    Translation:HumansCells
    142. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S, Rahman MU. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008 Apr; 58(4):964-75. PMID: 18383539.
      Citations: 100     Fields:    Translation:Humans
    143. Kay J, Bazari H, Avery LL, Koreishi AF. Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med. 2008 Feb 21; 358(8):827-38. PMID: 18287606.
      Citations: 14     Fields:    Translation:Humans
    144. Kay J. Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med. 2008 Feb; 75(2):112, 114, 117. PMID: 18290354.
      Citations: 4     Fields:    Translation:Humans
    145. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007 Oct; 56(10):3433-41. PMID: 17907148.
      Citations: 41     Fields:    Translation:Humans
    146. Cha JH, Furie K, Kay J, Walensky RP, Mullins ME, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 39-2006. A 24-year-old woman with systemic lupus erythematosus, seizures, and right arm weakness. N Engl J Med. 2006 Dec 21; 355(25):2678-89. PMID: 17182994.
      Citations: 2     Fields:    Translation:HumansAnimals
    147. Sarraf P, Kay J, Friday RP, Reginato AM. Wegener's granulomatosis: is biologic therapy useful? Curr Rheumatol Rep. 2006 Aug; 8(4):303-11. PMID: 16839510.
      Citations: 3     Fields:    Translation:HumansAnimals
    148. Kay J, Finn DS, Stone JR. Case records of the Massachusetts General Hospital. Case 4-2006. A 79-year-old woman with myalgias, fatigue, and shortness of breath. N Engl J Med. 2006 Feb 09; 354(6):623-30. PMID: 16467550.
      Citations: 3     Fields:    Translation:Humans
    149. Kay J, McCluskey RT. Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency. N Engl J Med. 2005 Oct 13; 353(15):1605-13. PMID: 16221784.
      Citations: 2     Fields:    Translation:Humans
    150. Moschella SL, Kay J, Mackool BT, Liu V. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med. 2004 Nov 18; 351(21):2219-27. PMID: 15548783.
      Citations: 9     Fields:    Translation:Humans
    151. Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2004 Jun; 43 Suppl 3:iii2-iii9. PMID: 15150426.
      Citations: 93     Fields:    Translation:HumansAnimalsCells
    152. Saudek DM, Kay J. Advanced glycation endproducts and osteoarthritis. Curr Rheumatol Rep. 2003 Feb; 5(1):33-40. PMID: 12590883.
      Citations: 23     Fields:    Translation:Humans
    153. Casato M, Mecucci C, Agnello V, Fiorilli M, Knight GB, Matteucci C, Gao L, Kay J. Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood. 2002 Mar 15; 99(6):2259-61. PMID: 11877309.
      Citations: 15     Fields:    Translation:HumansCells
    154. Hou FF, Miyata T, Boyce J, Yuan Q, Chertow GM, Kay J, Schmidt AM, Owen WF. beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int. 2001 Mar; 59(3):990-1002. PMID: 11231354.
      Citations: 19     Fields:    Translation:HumansCells
    155. Salahuddin N, Libman BS, Lunde JH, Kay J, Cooper SM. The association of relapsing polychondritis and myelodysplastic syndrome: report of three cases. J Clin Rheumatol. 2000 Jun; 6(3):146-9. PMID: 19078463.
      Citations: 1     Fields:    
    156. Kay J, Bardin T. Osteoarticular disorders of renal origin: disease-related and iatrogenic. Baillieres Best Pract Res Clin Rheumatol. 2000 Jun; 14(2):285-305. PMID: 10925746.
      Citations: 3     Fields:    Translation:Humans
    157. Kay JH, Altshuler LL, Ventura J, Mintz J. Prevalence of axis II comorbidity in bipolar patients with and without alcohol use disorders. Ann Clin Psychiatry. 1999 Dec; 11(4):187-95. PMID: 10596733.
      Citations: 8     Fields:    Translation:Humans
    158. Kay J. Beta 2-microglobulin amyloidosis in renal failure: understanding this recently recognized condition. Cleve Clin J Med. 1999 Mar; 66(3):145-7. PMID: 10079583.
      Citations: 4     Fields:    Translation:Humans
    159. Jimenez RE, Price DA, Pinkus GS, Owen WF, Lazarus JM, Kay J, Turner JR. Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis. Am J Surg Pathol. 1998 Jun; 22(6):729-35. PMID: 9630180.
      Citations: 5     Fields:    Translation:Humans
    160. Owen WF, Hou FF, Stuart RO, Kay J, Boyce J, Chertow GM, Schmidt AM. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int. 1998 May; 53(5):1365-73. PMID: 9573554.
      Citations: 12     Fields:    Translation:HumansCells
    161. Hou FF, Boyce J, Chertow GM, Kay J, Owen WF. Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. J Am Soc Nephrol. 1998 Feb; 9(2):277-83. PMID: 9527404.
      Citations: 6     Fields:    Translation:HumansCells
    162. Hou FF, Chertow GM, Kay J, Boyce J, Lazarus JM, Braatz JA, Owen WF. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Kidney Int. 1997 May; 51(5):1514-9. PMID: 9150467.
      Citations: 9     Fields:    Translation:HumansCells
    163. Chertow GM, Trimbur T, Karlson EW, Lazarus JM, Kay J. Performance characteristics of a dialysis-related amyloidosis questionnaire. J Am Soc Nephrol. 1996 Aug; 7(8):1235-40. PMID: 8866418.
      Citations: 1     Fields:    Translation:Humans
    164. Berarducci M, Thomas C, Kay J. Churg-strauss syndrome with diffuse gastrointestinal involvement. J Clin Rheumatol. 1996 Aug; 2(4):221-6. PMID: 19078069.
      Citations: 2     Fields:    
    165. Grevelink S, Moschella SL, Kay J. Dermatomyositis update. J Clin Rheumatol. 1995 Feb; 1(1):2-12. PMID: 19077934.
      Citations: 1     Fields:    
    166. Kay J, Czop JK. Enhancement of human monocyte beta-glucan receptors by glucocorticoids. Immunology. 1994 Jan; 81(1):96-102. PMID: 8132226.
      Citations: 2     Fields:    Translation:HumansCells
    167. Kay J, Preibisz JM. Lyme disease. Compr Ther. 1993; 19(4):157-62. PMID: 8261770.
      Citations:    Fields:    Translation:Humans
    168. Kay J, Benson CB, Lester S, Corson JM, Pinkus GS, Lazarus JM, Owen WF. Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum. 1992 Aug; 35(8):926-32. PMID: 1642657.
      Citations: 6     Fields:    Translation:Humans
    169. Gravallese EM, Baker N, Lester S, Kay J, Owen WF. Musculoskeletal manifestations in beta 2-microglobulin amyloidosis. Case discussion. Arthritis Rheum. 1992 May; 35(5):592-602. PMID: 1575795.
      Citations: 3     Fields:    Translation:Humans
    170. Czop JK, Kay J. Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes. J Exp Med. 1991 Jun 01; 173(6):1511-20. PMID: 1851799.
      Citations: 18     Fields:    Translation:HumansCells
    171. Kay J, Austen KF, Czop JK. Identification and characterization of opsonic fibronectin in synovial fluids of patients with active rheumatoid arthritis. Arthritis Rheum. 1991 Jun; 34(6):687-96. PMID: 1711322.
      Citations: 2     Fields:    Translation:HumansCells
    172. Matsuyama T, Yamada A, Kay J, Yamada KM, Akiyama SK, Schlossman SF, Morimoto C. Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex. J Exp Med. 1989 Oct 01; 170(4):1133-48. PMID: 2477485.
      Citations: 76     Fields:    Translation:HumansCells
    173. Kay J, Eichenfield AH, Athreya BH, Doughty RA, Schumacher HR. Synovial fluid eosinophilia in Lyme disease. Arthritis Rheum. 1988 Nov; 31(11):1384-9. PMID: 3056421.
      Citations: 1     Fields:    Translation:HumansCells
    174. Kay J, Stricker RB. Hematologic and immunologic abnormalities in anorexia nervosa. South Med J. 1983 Aug; 76(8):1008-10. PMID: 6348960.
      Citations: 4     Fields:    Translation:HumansCells
    175. Lee KC, Kay J, Wong M. Separation of functionally distinct subpopulations of Corynebacterium parvum-activated macrophages with predominantly stimulatory or suppressive effect on the cell-mediated cytotoxic T cell response. Cell Immunol. 1979 Jan; 42(1):28-41. PMID: 312146.
      Citations: 7     Fields:    Translation:AnimalsCells
    Kay's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (576)
    Explore
    _
    Co-Authors (14)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _